Skip to Main Content

Advertisement

Skip Nav Destination

Prospective validation of the prognostic relevance of CD34+CD38 AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement